DOTAGA-trastuzumab. A new antibody conjugate targeting HER2/Neu antigen for diagnostic purposes

Bioconjugate Chemistry

Volumn 23, Issue 6, 2012, Pages 1181-1188

  Moreau, Mathieu ^a   Raguin, Olivier ^b   Vrigneaud, Jean Marc ^c   Collin, Bertrand ^c   Bernhard, Claire ^a   Tizon, Xavier ^b   Boschetti, Frédéric ^d   Duchamp, Olivier ^b   Brunotte, François ^c   Denat, Franck ^a  

^a UNIVERSITÉ DE BOURGOGNE   (France)

^b Oncodesign   (France)

^c CENTRE GEORGES FRANÇOIS LECLERC   (France)

^d CheMatech   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CELL CULTURE; CHELATION; DIAGNOSIS; DISEASES; INDIUM; MEDICAL IMAGING; SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY; TUMORS;

ANTIBODY CONJUGATE; BIFUNCTIONAL CHELATING AGENT; CONDITION; DEGREE OF CONJUGATIONS; LABELINGS; MACROCYCLES; POST INJECTION; RADIOLABELLING; SYNTHESISED; TRASTUZUMAB;

MONOCLONAL ANTIBODIES;

2,2",2" [10 (2,6 DIOXOTETRAHYDRO 2H PYRAN 3 YL) 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7 TRIYL]TRIACETIC ACID ANHYDRIDE; CHELATING AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; INDIUM 111; MACROCYCLIC COMPOUND; MONOCLONAL ANTIBODY; TRASTUZUMAB; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING AFFINITY; BIOLOGICAL ACTIVITY; BREAST CANCER; CANCER CELL CULTURE; CHELATION; DRUG CONJUGATION; DRUG PURIFICATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; ISOTOPE LABELING; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MOUSE; NONHUMAN; PH; PROTEIN TARGETING; RADIOACTIVITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TUMOR XENOGRAFT;

ANHYDRIDES; ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; BREAST; BREAST NEOPLASMS; CELL LINE, TUMOR; FEMALE; HETEROCYCLIC COMPOUNDS, 1-RING; HUMANS; IMMUNOCONJUGATES; INDIUM RADIOISOTOPES; MICE; MICE, INBRED BALB C; MODELS, MOLECULAR; RECEPTOR, ERBB-2; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 84862668797     PISSN: 10431802     EISSN: 15204812     Source Type: Journal    
DOI: 10.1021/bc200680x     Document Type: Article

References (44)

1. Barbet, J., Kraeber-Bodere, F., and Chatal, J.-F. (2008) Review: what can be expected from nuclear medicine tomorrow? Cancer Biother. Radiopharm. 23, 483-504.
2. Wu, A. M. (2009) Antibodies and antimatter: the resurgence of immuno-PET. J. Nucl. Med. 50, 2-5.
3. Verel, I., Visser, G. W. M., and Van Dongen, G. A. (2005) The promise of immuno-PET in radioimmunotherapy. J. Nucl. Med. 46 (Suppl 1), 164S-71S.
4. Niu, G., Li, Z., Cao, Q., and Chen, X. (2009) Monitoring therapeutic response of human ovarian cancer to 17-DMAG by noninvasive PET imaging with 64Cu-DOTA-trastuzumab. Eur. J. Nucl. Med. Mol. Imaging 36, 1510-1519.
5. Ahlgren, S., Waallberg, H., Tran, T. A., Widstroem, C., Hjertman, M., Abrahmsen, L., Berndorff, D., Dinkelborg, L. M., Cyr, J. E., Feldwisch, J., Orlova, A., and Tolmachev, V. (2009) Targeting of HER2-expressing tumors with a site-specifically 99mTc-labeled recombinant affibody molecule, ZHER2:2395, with C-terminally engineered cysteine. J. Nucl. Med. 50, 781-789.
6. Tolmachev, V., Altai, M., Sandstrom, M., Perols, A., Karlstrom, A. E., Boschetti, F., and Orlova, A. (2011) Evaluation of a maleimido derivative of NOTA for site-specific labeling of affibody molecules. Bioconjugate Chem. 22, 894-902.
7. Olafsen, T., and Wu, A. M. (2010) Antibody vectors for imaging. Semin. Nucl. Med. 40, 167-181.
8. Bange, J., Zwick, E., and Ullrich, A. (2001) Molecular targets for breast cancer therapy and prevention. Nat. Med. 7, 548-552.
9. Smith, I., Procter, M., Gelber, R. D., Guillaume, S., Feyereislova, A., Dowsett, M., Goldhirsch, A., Untch, M., Mariani, G., Baselga, J., Kaufmann, M., Cameron, D., Bell, R., Bergh, J., Coleman, R., Wardley, A., Harbeck, N., Lopez, R. I., Mallmann, P., Gelmon, K., Wilcken, N., Wist, E., Sánchez Rovira, P., and Piccart-Gebhart, M. J. (2007) 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. The Lancet 369, 29-36.
10. Owens, M., Horten, B., and Da Silva, M. (2004) HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues. Clin. Breast Cancer 5, 63-69.
11. Pestrin, M., Bessi, S., Galardi, F., Truglia, M., Biggeri, A., Biagioni, C., Cappadona, S., Biganzoli, L., Giannini, A., and Di Leo, A. (2009) Correlation of HER2 status between primary tumors and corresponding circulating tumor cells in advanced breast cancer patients. Breast Cancer Res. Treat. 118, 523-530.
12. Munzone, E., Nolé, F., Goldhirsch, A., Botteri, E., Esposito, A., Zorzino, L., Curigliano, G., Minchella, I., Adamoli, L., Cassatella, M. C., Casadio, C., and Sandri, M. T. (2010) Changes of HER2 status in circulating tumor cells compared with the primary tumor during treatment for advanced breast cancer. Clin. Breast Cancer 10, 392-397.
13. Palm, S., Enmon, R. M., Jr., Matei, C., Kolbert, K. S., Xu, S., Zanzonico, P. B., Finn, R. L., Koutcher, J. A., Larson, S. M., and Sgouros, G. (2003) Pharmacokinetics and biodistribution of 86Y-trastuzumab for 90Y dosimetry in an ovarian carcinoma model: Correlative microPET and MRI. J. Nucl. Med. 44, 1148-1155.
14. Lub-de Hooge, M. N., Kosterink, J. G., Perik, P. J., Nijnuis, H., Tran, L., Bart, J., Suurmeijer, A. J., De Jong, S., Jager, P. L., and De Vries, E. G. (2004) Preclinical characterisation of 111In-DTPA-trastuzumab. Br. J. Pharmacol. 143, 99-106.
15. Perik, P. J., Lub-de Hooge, M. N., Gietema, J. A., Van der Graaf, W. T. A., De Korte, M. A., Jonkman, S., Kosterink, J. G. W., Van Veldhuisen, D. J., Sleijfer, D. T., Jager, P. L., and De Vries, E. G. E. (2006) Indium-111-labeled trastuzumab scintigraphy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J. Clin. Oncol. 24, 2276-2282.
16. Dennis, M. S., Jin, H. K., Dugger, D., Yang, R. H., McFarland, L., Ogasawara, A., Williams, S., Cole, M. J., Ross, S., and Schwall, R. (2007) Imaging tumors with an albumin-binding Fab, a novel tumor-targeting agent. Cancer Res. 67, 254-261.
17. Dijkers, E. C. F., Kosterink, J. G. W., Rademaker, A. P., Perk, L. R., Van Dongen, G. A. M. S., Bart, J., De Jong, J. R., De Vries, E. G. E., and Lub-de Hooge, M. N. (2009) Development and characterization of clinical-grade 89Zr-trastuzumab for HER2/neu immunolPET imaging. J. Nucl. Med. 50, 974-981.
18. Rasaneh, S., Rajabi, H., Babaei, M. H., Daha, F. J., and Salouti, M. (2009) Radiolabeling of trastuzumab with (177)Lu via DOTA, a new radiopharmaceutical for radioimmunotherapy of breast cancer. Nucl. Med. Biol. 36, 363-369.
19. Oude Munnink, T. H., De Korte, M. A., Nagengast, W. B., Timmer-Bosscha, H., Schroeder, C. P., De Jong, J. R., Van Dongen, G. A. M. S., Jensen, M. R., Quadt, C., Lub-de Hooge, M. N., and De Vries, E. G. E. (2010) 89Zr-trastuzumab PET visualises HER2 downregulation by the HSP90 inhibitor NVP-AUY922 in a human tumour xenograft. Eur. J. Cancer 46, 678-684.
20. Zeglis, B. M., Mohindra, P., Weissmann, G. I., Divilov, V., Hilderbrand, S. A., Weissleder, R., and Lewis, J. S. (2011) A modular strategy for the construction of radiometallated antibodies for positron emission tomography based on inverse electron demand Diels-Alder click chemistry. Bioconjugate Chem., 2048-2059.
21. Camera, L., Kinuya, S., Garmestani, K., Wu, C. C., Brechbiel, M. W., Pai, L. H., McMurry, T. J., Gansow, O. A., Pastan, I., Paik, C. H., and Carrasquillo, J. A. (1994) Evaluation of the serum stability and invivo biodistribution of Chx-Dtpa and other ligands for yttrium labeling of monoclonal-antibodies. J. Nucl. Med. 35, 882-889.
22. Cutler, C. S., Smith, C. J., Ehrhardt, G. J., Tyler, T. T., Jurisson, S. S., and Deutsch, E. (2000) Current and potential therapeutic uses of lanthanide radioisotopes. Cancer Biother. Radiopharm. 15, 531-545.
23. Smith-Jones, P. M., Vallabahajosula, S., Goldsmith, S. J., Navarro, V., Hunter, C. J., Bastidas, D., and Bander, N. H. (2000) In vitro characterization of radiolabeled monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen. Cancer Res. 60, 5237-5243.
24. McMurry, T. J., Brechbiel, M., Kumar, K., and Gansow, O. A. (1992) Convenient synthesis of bifunctional tetraaza macrocycles. Bioconjugate Chem. 3, 108-17.
25. Mishra, A. K., Gestin, J. F., Benoist, E., FaivreChauvet, A., and Chatal, J. F. (1996) Simplified synthesis of the bifunctional chelating agent 2-(4-aminobenzyl)-1,4,7,10-tetraazacyclododecane-N,N′,N″, N‴-tetraacetic acid. New J. Chem. 20, 585-588.
26. Maecke, H. R., Eisenwiener, K. P., and Powell, P. (2000) A convenient synthesis of novel bifunctional prochelators for coupling to bioactive peptides for radiometal labelling. Bioorg. Med. Chem. Lett. 10, 2133-2135.
27. Botta, M., Kielar, F., Tei, L., and Terreno, E. (2010) Large relaxivity enhancement of paramagnetic lipid nanoparticles by restricting the local motions of the Gd(III) chelates. J. Am. Chem. Soc. 132, 7836.
28. Mayer, H. A., Henig, J., Toth, E., Engelmann, J., and Gottschalk, S. (2010) Macrocyclic Gd(3+) chelates attached to a silsesquioxane core as potential magnetic resonance imaging contrast agents: synthesis, physicochemical characterization, and stability studies. Inorg. Chem. 49, 6124-6138.
29. Cordier, D., Forrer, F., Kneifel, S., Sailer, M., Mariani, L., Maecke, H., Muller-Brand, J., and Merlo, A. (2010) Neoadjuvant targeting of glioblastoma multiforme with radiolabeled DOTAGA-substance P-results from a phase I study. J. Neurooncol. 100, 129-136.
30. Lux, F., Mignot, A., Mowat, P., Louis, C., Dufort, S., Bernhard, C., Denat, F., Boschetti, F., Brunet, C., Antoine, R., Dugourd, P., Laurent, S., Elst, L. V., Muller, R., Sancey, L., Josserand, V., Coll, J.-L., Stupar, V., Barbier, E., Remy, C., Broisat, A., Ghezzi, C., Le, D. G., Roux, S., Perriat, P., and Tillement, O. (2011) Ultrasmall rigid particles as multimodal probes for medical applications. Angew. Chem., Int. Ed. 50, 12299-12303.
31. Lasfargues, E. Y., Coutinho, W. G., and Redfield, E. S. (1978) Isolation of two human tumor epithelial cell lines from solid breast carcinomas. J. Natl. Cancer Inst. 61, 967-78.
32. Gazdar, A. F., Kurvari, V., Virmani, A., Gollahon, L., Sakaguchi, M., Westerfield, M., Kodagoda, D., Stasny, V., Cunningham, H. T., Wistuba, I. I., Tomlinson, G., Tonk, V., Ashfaq, R., Leitch, A. M., Minna, J. D., and Shay, J. W. (1998) Characterization of paired tumor and non-tumor cell lines established from patients with breast cancer. Int. J. Cancer 78, 766-74.
33. Workman, P., Aboagye, E. O., Balkwill, F., Balmain, A., Bruder, G., Chaplin, D. J., Double, J. A., Everitt, J., Farningham, D. A. H., Glennie, M. J., Kelland, L. R., Robinson, V., Stratford, I. J., Tozer, G. M., Watson, S., Wedge, S. R., and Eccles, S. A. (2010) Guidelines for the welfare and use of animals in cancer research. Br. J. Cancer 102, 1555-77.
34. Hnatowich, D. J., Childs, R. L., Lanteigne, D., and Najafi, A. (1983) The preparation of DTPA-coupled antibodies radiolabeled with metallic radionuclides: an improved method. J. Immunol. Methods 65, 147-57.
35. Hnatowich, D. J., Layne, W. W., Childs, R. L., Lanteigne, D., Davis, M. A., Griffin, T. W., and Doherty, P. W. (1983) Radioactive labeling of antibody: a simple and efficient method. Science 220, 613-5.
36. Ferreira, C. L., Yapp, D. T. T., Crisp, S., Sutherland, B. W., Ng, S. S. W., Gleave, M., Bensimon, C., Jurek, P., and Kiefer, G. E. (2010) Comparison of bifunctional chelates for (64)Cu antibody imaging. Eur. J. Nucl. Med. Mol. Imaging 37, 2117-2126.
37. Chong, H. S., Song, H. A., Kang, C. S., Baidoo, K. E., Milenic, D. E., Chen, Y. W., Dai, A. Z., and Brechbiel, M. W. (2011) Efficient bifunctional decadentate ligand 3p-C-DEPA for targeted alpha-radioimmunotherapy applications. Bioconjugate Chem. 22, 1128-1135.
38. Liu, S., He, Z., Hsieh, W.-Y., and Fanwick, P. E. (2003) Synthesis, characterization, and X-ray crystal structure of In(DOTAAA) (AA = p-Aminoanilide): a model for 111In-labeled DOTA-biomolecule conjugates. Inorg. Chem. 42, 8831-8837.
39. Colvin, M. E., Lau, E. Y., and Lightstone, F. C. (2006) Environmental effects on the structure of metal ion-DOTA complexes: An ab initio study of radiopharmaceutical metals. Inorg. Chem. 45, 9225-9232.
40. Wadas, T. J., Wong, E. H., Weisman, G. R., and Anderson, C. J. (2010) Coordinating radiometals of copper, gallium, indium, yttrium, and zirconium for PET and SPECT imaging of disease. Chem. Rev. 110, 2858-2902.
41. Mather, S. J., Cooper, M. S., and Sabbah, E. (2006) Conjugation of chelating agents to proteins and radiolabeling with trivalent metallic isotopes. Nat. Protoc. 1, 314-317.
42. Jurisson, S. S., Mohsin, H., Fitzsimmons, J., Shelton, T., Hoffman, T. J., Cutlerc, C. S., Lewis, M. R., Atheye, P. S., Gulyas, G., Kiefer, G. E., Frank, R. K., Simon, J., and Lever, S. Z. (2007) Preparation and biological evaluation of In-111-, Lu-177- and Y-90- labeled DOTA analogues conjugated to B72.3. Nucl. Med. Biol. 34, 493-502.
43. Luo, T.-Y., Tang, I. C., Wu, Y.-L., Hsu, K.-L., Liu, S.-W., Kung, H.-C., Lai, P.-S., and Lin, W.-J. (2009) Evaluating the potential of 188Re-SOCTA-trastuzumab as a new radioimmunoagent for breast cancer treatment. Nucl. Med. Biol. 36, 81-88.
44. McLarty, K., Cornelissen, B., Scollard, D. A., Done, S. J., Chun, K., and Reilly, R. M. (2009) Associations between the uptake of 111In-DTPA-trastuzumab, HER2 density and response to trastuzumab (Herceptin) in athymic mice bearing subcutaneous human tumour xenografts. Eur. J. Nucl. Med. Mol. Imaging 36, 81-93.